Myriad Genetics Inc (MYGN)

Financial leverage ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Total assets	US$ in thousands	1,081,300	1,085,100	1,110,500	1,146,500	1,149,100	1,187,200	1,169,300	1,198,700	1,212,000	1,210,200	1,255,400	1,320,700	1,335,900	1,360,300	1,336,900	1,444,500	1,404,600	1,446,700	1,578,300	1,591,200
Total stockholders’ equity	US$ in thousands	731,700	740,500	760,000	783,200	683,400	735,200	835,200	885,800	916,600	947,400	950,100	967,800	968,600	902,500	875,200	909,300	918,200	967,200	1,077,200	1,074,500
Financial leverage ratio		1.48	1.47	1.46	1.46	1.68	1.61	1.40	1.35	1.32	1.28	1.32	1.36	1.38	1.51	1.53	1.59	1.53	1.50	1.47	1.48

September 30, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,081,300K ÷ $731,700K
= 1.48

The financial leverage ratio of Myriad Genetics Inc has exhibited some fluctuations over the past several quarters. The ratio has generally been within a range of 1.28 to 1.68, indicating the company has been using debt to finance its operations and investments.

The trend of the financial leverage ratio shows some variability, with a peak of 1.68 in the third quarter of 2023, followed by a decrease in subsequent quarters before rising again in the first quarter of 2024. This indicates that the company's reliance on debt has fluctuated over the periods analyzed.

Overall, the financial leverage ratio of Myriad Genetics Inc suggests that the company has been moderately leveraged, with a level of debt that is manageable within its operations. It is important for investors and stakeholders to continue monitoring this ratio to assess the company's debt management and financial health.